WVE — Wave Life Sciences, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1631574 ·
Last close
$3.67
Market Cap
$723.17M
52W High
$21.73
52W Low
$3.60
ADV30
3,238,951
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 38,246,000 | — | -31,298,000 | -26,087,000 | 583,544,000 | 544,591,000 | 71,814,000 |
| Dec 2025 | 17,245,000 | — | -56,467,000 | -53,179,000 | 638,499,000 | 602,068,000 | 120,142,000 |
| Sep 2025 | 7,608,000 | — | -56,353,000 | -53,852,000 | 241,378,000 | 196,218,000 | 116,829,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-184,007,000
Investing CF
$-991,000
Financing CF
$486,607,000
CapEx
$-1,157,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.09
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,352,323,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-196,877,000
Pretax Income TTM
$-183,587,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$65,371,000
EBITDA
$-214,520,000
Free Cash Flow
$-128,778,376
Enterprise Value
$457,439,136
Total Cash
$490,601,984
Total Debt
$43,590,000
Shares Out
197,048,175
Trailing EPS
$-1.08
Book Value
$2.76
ROE
-67.4%
ROA
-33.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 42,727,000 | -215,383,000 | -204,378,000 | 638,499,000 | 120,142,000 | 518,357,000 | -187,493,000 |
| Dec 2024 | 108,302,000 | -110,403,000 | -97,008,000 | 352,207,000 | 142,692,000 | 209,515,000 | -151,026,000 |
| Dec 2023 | 113,305,000 | -67,996,000 | -57,513,000 | 274,949,000 | 235,319,000 | 39,630,000 | -19,431,000 |
| Dec 2022 | 3,649,000 | -162,720,000 | -161,823,000 | 146,386,000 | 191,477,000 | -45,091,000 | -127,781,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.14
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $5.00 · spot: $3.67 · call volume: 126 · put volume: 24
Expected Move to 2026-12-18:
±$2.15
(58.58%) —
implied range
$1.52 –
$5.82
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMMP | IMMUTEP Ltd | $719.18M | $4.88 | — |
| VSTM | Verastem, Inc. | $703.68M | $7.77 | — |
| PHAR | Pharming Group N.V. | $744.59M | $10.52 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $701.51M | $22.63 | — |
| SLNCF | Silence Therapeutics plc | $745.85M | $4.00 | — |
News headlines (Yahoo Finance, 1h cache)
Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for Obesity
2026-09-23 11:30 · Yahoo
Wave Life Sciences to Present at Cantor 2026 Global Healthcare Conference
2026-09-03 20:05 · Yahoo
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
2026-08-13 13:05 · Yahoo
Wave Life Sciences Announces Expected Completion Date for Redomiciliation to Delaware
2026-08-05 20:05 · Yahoo
Wave Life Sciences to Present at Upcoming Investor Conferences
2026-08-04 12:30 · Yahoo
Wave Life Sciences (WVE) Q2 2026 Earnings Call Transcript
2026-08-04 00:16 · Yahoo
WAVE Life Sciences Q2 Earnings Call Highlights
2026-07-30 21:03 · Yahoo
WAVE Life Sciences Ltd (WVE) (Q2 2026) Earnings Call Highlights: Strong Cash Position and ...
2026-07-30 21:03 · Yahoo
Wave Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-07-30 11:30 · Yahoo
4 RNA Therapeutics Stocks Leading the Next Wave of Innovation
2026-09-28 13:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.